PMC:7755033 / 30548-30897 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"520","span":{"begin":294,"end":296},"obj":"Species"}],"attributes":[{"id":"A520","pred":"tao:has_database_id","subj":"520","obj":"Tax:126910"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"rule of five (PASS analysis)\nIn the drug discovery context, it is generally believed that an orally active drug candidate cannot have more than one violation of Lipinski’s criteria otherwise it might compromise its bioavailability (Balakrishnan et al., 2014).\nBased on Lipinski's rule of five, WS phytoconstituents were previously screened and selec"}

{"project":"LitCovid-sentences","denotations":[{"id":"T266","span":{"begin":29,"end":259},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"rule of five (PASS analysis)\nIn the drug discovery context, it is generally believed that an orally active drug candidate cannot have more than one violation of Lipinski’s criteria otherwise it might compromise its bioavailability (Balakrishnan et al., 2014).\nBased on Lipinski's rule of five, WS phytoconstituents were previously screened and selec"}